Monopar Therapeutics Inc.
MNPR
$41.91
-$1.24-2.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -737.66% | 23.96% | -4.51% | 9.52% | 7.16% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,326.37% | -40.46% | 1.73% | -30.68% | 0.02% |
| Change in Net Operating Assets | 12,822.08% | 110.71% | 13.71% | -66.29% | 55.19% |
| Cash from Operations | -86.16% | 35.98% | -1.29% | -7.08% | 20.31% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,554.64% | 41,170.83% | 99.76% | -133.10% | 22,774.81% |
| Cash from Investing | -1,554.64% | 41,170.83% | 99.76% | -133.10% | 22,774.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | 839.28% | 33.35% |
| Repurchase of Common Stock | -305.45% | -65.00% | 6.54% | -101.89% | 35.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 340,323.03% | -66.67% | -100.31% | 851.24% | 35.59% |
| Foreign Exchange rate Adjustments | -184.44% | 200.00% | 188.24% | 79.76% | -223.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39,975.95% | 94.09% | -411.65% | -69.07% | 203.02% |